New insights into how DMTs may affect COVID-19 outcomes

neurodiem-image

In a COVID-19 session at MSVirtual2020, specialists reported data – sometimes conflicting – from several studies investigating links between disease modifying therapies (DMTs) and COVID-19 outcomes.

Dr Steve Simpson-Yap from the University of Melbourne, Australia, presented the first results from the MS Global Data Sharing Initiative, with data on 1,540 MS patients, including 476 with suspected COVID-19 and 776 with confirmed COVID-19.

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.